Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
36.85 +0.04 (+0.11%) 02/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 36.85 unch (unch) 17:02 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
36.38
Day High
38.05
Open 37.94
Previous Close 36.81 36.81
Volume 2,509,000 2,509,000
Avg Vol 2,798,545 2,798,545
Stochastic %K 76.77% 76.77%
Weighted Alpha +27.51 +27.51
5-Day Change +5.29 (+16.76%) +5.29 (+16.76%)
52-Week Range 21.62 - 39.47 21.62 - 39.47
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,964,281
  • Shares Outstanding, K 188,990
  • Annual Sales, $ 9,300 K
  • Annual Income, $ -643,200 K
  • EBIT $ -544 M
  • EBITDA $ -538 M
  • 60-Month Beta 1.07
  • Price/Sales 31.35
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 56.28% ( -1.53%)
  • Historical Volatility 71.45%
  • IV Percentile 27%
  • IV Rank 14.39%
  • IV High 151.63% on 11/18/24
  • IV Low 40.25% on 07/23/24
  • Put/Call Vol Ratio 0.23
  • Today's Volume 4,914
  • Volume Avg (30-Day) 3,884
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 119,024
  • Open Int (30-Day) 109,007

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.90
  • Number of Estimates 4
  • High Estimate -0.76
  • Low Estimate -1.03
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -1,700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.50 +20.82%
on 02/12/25
Period Open: 36.08
39.47 -6.64%
on 02/20/25
+0.77 (+2.13%)
since 01/21/25
3-Month
22.47 +64.00%
on 11/22/24
Period Open: 23.24
39.47 -6.64%
on 02/20/25
+13.61 (+58.56%)
since 11/21/24
52-Week
21.62 +70.44%
on 06/24/24
Period Open: 34.16
39.47 -6.64%
on 02/20/25
+2.69 (+7.87%)
since 02/21/24

Most Recent Stories

More News
BridgeBio Pharma: Q4 Earnings Snapshot

BridgeBio Pharma: Q4 Earnings Snapshot

BBIO : 36.85 (+0.12%)
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

BBIO : 36.85 (+0.12%)
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

BBIO : 36.85 (+0.12%)
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

BBIO : 36.85 (+0.12%)
Brian's Big Idea: Healthcare Stocks

One of the most difficult sectors to invest in is the healthcare sector. Not only do you have to be nuanced in the ways of the stock market but you also have to have a deep understanding of medicines,...

VCYT : 39.18 (-4.56%)
HIMS : 49.28 (-25.79%)
BBIO : 36.85 (+0.12%)
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

BBIO : 36.85 (+0.12%)
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

BBIO : 36.85 (+0.12%)
Is This Biotech Stock With 150% Upside a Buy Now?

The high price estimate for BridgeBio Pharma suggests potential upside of 150% in 2025.

BAYRY : 5.7600 (+0.35%)
AZN : 74.22 (-0.46%)
$SPX : 6,013.13 (-1.71%)
BBIO : 36.85 (+0.12%)
PFE : 26.30 (+1.54%)
BridgeBio Pharma, Inc. Announces Positive CHMP Recommendation for Acoramidis for ATTR-CM Treatment in Europe

CHMP recommends acoramidis for EU approval based on positive Phase 3 study results, with a final decision expected soon.Quiver AI SummaryThe Committee for Medicinal Products for Human Use (CHMP) has recommended...

BBIO : 36.85 (+0.12%)
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BBIO : 36.85 (+0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United...

See More

Key Turning Points

3rd Resistance Point 39.47
2nd Resistance Point 38.76
1st Resistance Point 37.81
Last Price 36.85
1st Support Level 36.14
2nd Support Level 35.43
3rd Support Level 34.47

See More

52-Week High 39.47
Last Price 36.85
Fibonacci 61.8% 32.65
Fibonacci 50% 30.55
Fibonacci 38.2% 28.44
52-Week Low 21.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements